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tion between items while indicating how strongly an item is preferred. This study 
investigated the use of MaxDiff as a means of determining patient-reported impor-
tance of medication treatment attributes. Methods: MaxDiff was used in a survey 
of rheumatoid arthritis (RA) patients to determine the importance and relative 
rank of specific attributes of RA treatments. The following attributes were selected 
based upon literature review and opinions of the research team: 1) Reduces pain; 2) 
Potential side effects; 3) How often treatment taken; 4) How treatment is given; 5) 
Where treatment is given; 6) Personal costs; 7) Works quickly; 8) How long treatment 
effects last; 9) Keeps disease from getting worse; and 10) Improves physical abilities. 
Respondents were shown 10 sets of 4 attributes and, for each set, were asked to 
indicate the RA treatment attribute that was most important and least important 
to them. The attribute sets were selected using an experimental design that showed 
each attribute an equal number of times and in different order within the sets. 
Hierarchical Bayesian techniques were used to derive respondent-level attribute 
importance scores and, based on the importance scores a relative rank order was 
developed for each attribute. Results: Based on 291 surveys, MaxDiff attribute 
importance scores ranged from 13 to 209 with higher scores indicating increased 
importance. Preventing the disease from getting worse, improving physical abili-
ties, and reduction in pain were the most important RA treatment attributes, all 
having scores > 195, while the ‘how’, ‘when’, and ‘where’ treatment administration 
attributes were the least important, all having scores < 15. ConClusions: MaxDiff 
importance scores demonstrated discrimination among attributes and respondents 
and should be considered as an alternative to more traditional ranking and rating 
approaches.
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Expensive rare disease treatments pose a problem for decision makers who are 
expected to judiciously allocate health care dollars to maximize benefit. If the 
Canadian public prioritize rare diseases for funding given their opportunity cost, 
this would reveal their value for rare disease treatment. This preference would 
in turn justify devoting limited resources to these conditions. objeCtives: 
Determine whether society 1) values the treatment of rare diseases over common 
diseases and, 2) accepts the opportunity costs associated with funding high-cost 
medications. Methods: In an online survey, 2211 subjects from across Canada 
were presented with 13 scenarios asking them choose between funding a rare dis-
ease, and either a common disease or societal benefit in a simple trade-off design. 
Embedded in the scenarios were factors and values related to rarity. Results: The 
rare disease was favoured by the majority of subjects in only 2 scenarios out of 9 
where the alternate was a common disease, and in 3 scenarios out of 4 where the 
alternate was a societal benefit. Canadians preferred to fund rare disease treat-
ment over education, recreation or smoking cessation programs. Factors which 
resulted in greater than 30% of subjects selecting the rare disease included unmet 
need, disease severity and young age. As treatment costs for the rare disease 
increased, it was increasingly less likely to be funded over the common disease. 
Knowing someone with, or having a rare disease was significantly associated with 
favouring the rare disease in 10 out of 13 scenarios. ConClusions: Canadians 
prefer to use resources to fund treatment of rare diseases over other societal 
benefits including recreation and education; however, they prefer to maximize 
health care resources to benefit the greatest number of people. Rare diseases are 
valued by Canadians only when the opportunity cost to treat them does not take 
away from common disease treatments.
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objeCtives: Although a growing number of treatment options are available for 
metastatic breast cancer (mBC), each treatment is associated with its own various 
advantages and disadvantages. It remains unclear how patients value the differ-
ent treatment characteristics and whether preferences vary as a function of prior 
treatment experience. Methods: Data were collected through a cross-sectional 
Internet survey of 181 women diagnosed with mBC who had prior experience 
with either a taxane, paclitaxel, or docetaxel. Patients provided demographic, 
health history, and health outcomes information. Participants also completed a 
choice-based conjoint exercise that included a series of choice questions. Each 
choice question included a pair of hypothetical treatments which were presented 
in terms of eight safety attributes (alopecia, motor neuropathy, myalgia/arthralgia, 
nausea/vomiting, fatigue, neutropenia, mucositis/stomatitis, and diarrhea), one 
effectiveness attribute, one dosing regimen attribute, and one quality of life attrib-
ute. Choice task data were analyzed using hierarchical Bayesian logistic regres-
sion models. Relative importances (RI) were reported and provide the magnitude 
of each attribute’s influence on treatment preference on a common ratio scale 
(e.g., an RI of 50% is twice as influential as an RI of 25%). Results: Women had 
a mean age of 52.24 years and 93.92% were non-Hispanic white. Effectiveness 
(RI= 33.49%) was most strongly associated with treatment preference, followed 
by alopecia (RI= 21.32%), fatigue (RI= 12.46%), neutropenia (RI= 10.37%), and qual-
ity of life (RI= 7.69%). Myalgia (RI= 0.48%), mucositis (RI= 0.43%), and dosing regi-
men (RI= 0.14%) had the weakest associations with preference. These preferences 
did not vary as a function of chemotherapy experience. ConClusions: Despite 
the risk of serious adverse events, incremental survival (1-3 months) is influential 
in patient preferences for chemotherapy. Furthermore, quality of life improve-
ments were more influential in treatment preferences than most adverse events. 
These findings help clarify the patient perspective of mBC treatments which, 
if aligned with prescribing patterns, may maximize treatment satisfaction and 
adherence.
37-40 per 1000 for hypertension, 22-26 for heart disease, 15-18 for diabetes, and 6-9 
for cancer, COPD, and stroke. The strongest predictors of disease onset were insur-
ance status, behavioral risk factors, and comorbid conditions. ConClusions:  The 
Population Health Model we developed is a health economic evaluation tool, which 
can predict future health outcomes for a cohort of Massachusetts residents over 
50 based on their individual characteristics. The simulation results were validated 
using selected national datasets (US and Canada). Our next step is to predict health 
care costs over time based on the health status micro-simulation and information 
from both the Medical Expenditure Panel Survey and Massachusetts insurance 
claims data.
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objeCtives: Discrete event simulation (DES) models are becoming more popu-
lar with modellers undertaking cost-effectiveness analyses. However, there is a 
dearth of empirical examples directly comparing DES with Markov cohort models 
(MM). This study applied these methods to a common dataset describing an ortho-
paedic physiotherapy screening clinic and multidisciplinary service (OPSC) versus 
usual orthopaedic care (UOC) to compare the empirical differences between these 
modelling methods and evaluate the cost-effectiveness of OPSC. Methods:  A 
MM and a DES were constructed using TreeAge Pro and Simul8, respectively. Data 
were obtained from hospital administrative sources and a retrospective chart audit 
of 980 patients with a primary diagnosis involving the knee, shoulder or lumbar 
spine attending an OPSC. Detailed analyses of disaggregated cost and effect esti-
mates generated by each model are performed. Uncertainty in each model is inves-
tigated using probabilistic sensitivity analyses (PSA). Results:  Both economic 
models generated similar costs estimates (MM-UOC= $1287; DES-UOC = $1322; 
MM-OPSC= $1403; DES-OPSC= $1419; MM incremental cost (IC)= $116; DES IC= $97). 
Each model generated comparable quality-adjusted life year saved (QALY) estimates 
(MM-UOC= 2.74; DES-UOC= 2.72; MM-OPSC= 2.81; DES-OPSC= 2.79; MM incremental 
effect (IE)= 0.066; DES IE= 0.068). The incremental cost-effectiveness ratios (ICERs) 
generated by the MM and DES were $1756 and $1418 per QALY, respectively. The 
DES model required a considerably longer time to develop and to run (DES run-
time= 80min; MM run-time= 11.8 seconds). However, the DES provided more explicit 
timing of events. ConClusions:  The MM and DES generated similar ICER esti-
mates, which suggest OPSC is cost-effective when compared to UOC. Empirical 
comparisons using the same data source have highlighted differences in develop-
ment and computational time between the MM and DES. The explicit management 
of time in DES also has the potential to generate different results than described by 
the MM. The limitations of this study are also considered.
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objeCtives: Preference values for prostate cancer specific health states vary greatly 
between studies and are influenced by the method of elicitation and study popula-
tion. Given the strengths, limitations, and potential for biases of both patient and 
societal preference values, understanding the magnitude of difference is pertinent 
for application in cost-effectiveness analysis. The objective of this study was to com-
pare patient preferences with those of the general population for several prostate 
cancer specific health states. Methods: Health state descriptions were developed 
with attributes that varied across five different health domains pertinent to men 
with prostate cancer: sexual function, urinary function, bowel function, pain, and 
emotional well-being. Men with prostate cancer and a representation of the general 
population (men and women) assigned preferences to 16 health states using a visual 
analog scale and standard gamble methodology. Study subjects also completed the 
Health Utilities Index mark 3 (HUI3) to obtain utility values using a generic prefer-
ence measure. Results: A total of 84 participants were enrolled (n= 43 prostate 
cancer; n= 41 general population) and completed the health state valuations. The 
mean age of the men with prostate cancer was 63.4 years (5.46) and 38.8 years (10.7) 
for the general population group. There was a statistically significant difference in 
HUI3 current health ratings between groups: men with prostate cancer HUI3: 0.74 
(standard error; se= 0.23) vs 0.88 (se= 0.19) for the general population (p= 0.006). The 
mean standard gamble utility values for the prostate cancer health states ranged 
from 0.85 to 0.46 among men with prostate cancer and from 0.81 to 0.32 among the 
non-cancer group. Two-group mean comparison test did not indicate statistical 
significance for the 16 health states (p-value: 0.93 - 0.09). ConClusions: There 
were no statistically significant differences in standard gamble valuations of pros-
tate cancer specific health states when comparing the patient perspective with 
the societal perspective.
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objeCtives: Maximum Difference Scaling (MaxDiff) is a survey research technique 
for obtaining preference scores for a set of items that provides greater discrimina-
